Pharmaxon
	Developer of neurology and neuro-oncology drugs. The company engages in the discovery and development of drugs for nervous system disorders in which cell mobility is modified. The company\'s activities are currently concentrated on the development of therapies for spinal cord injury, memory disorders and glioblastoma. The company spun out of the Development Biology Institute of Marseille Luminy.
	['', 'neuro-oncology drugs', ' ', 'nervous system disorders', ' ', 'neurological drugs', '']
Cytion
	Developer of drug screening technology. The company has developed drug screening technology for the functional analysis of ion channel proteins.
	['', 'drug screening technology', ' ', 'ion channel protein', ' ', 'drug development', '']
Sirus
	Operator of a pharmaceutical research company. The company focuses on drug development for the treatment of nerve injury and muscle spasm by using its proprietary platform technologies that covers pain, emesis, epilepsy and insomnia.
	['', 'neurological disease', ' ', 'drug development', ' ', 'chemical properties', ' ', 'platform technologies', '']
Niagara Growth
	Provider of funding to businesses with less than one million dollars in assets and the potential for sustained high growth.
	['', 'fund provider', ' ', 'Canada', '']
Ancile Pharmaceuticals
	Developer of botanical drugs. The company has a multi-drug portfolio, which includes ANPH 101, an investigational drug with indications for sleep maintenance disorders.
	['', 'botanical drug', ' ', 'chronic disease', ' ', 'prescription botanical drug', '']
Venture Alliance
	Provider of seed capital and start-up executive management to commercialize technologies developed at national laboratories and other research institutions. The company has provided investments for the development of medical diagnostic devices, predictive maintenance hardware/software, restaurant software and electroless nickel plating technology.
	['', 'seed capital', ' ', 'start-up finance', ' ', 'commercialize technology', ' investment']
Proacta
	Developer of oncology drugs. The company provides cancer-related products which targets the physiological attributes of solid tumors through normal metabolic processes.
	['', 'oncology drug', ' ', 'cancer drug', ' ', 'solid tumour drug', '']
Coelacanth Chemical
	Provider of proprietary chemistry technologies to rapidly discover new chemical entities for drug development and discovery. The company uses its proprietary technology ClickChem to create sets of novel building blocks which are used for the production of innovative compound sets that shorten lead discovery and lead optimization time for drug development.
	['ClickChem , ', 'proprietary chemistry technologies', ' ', 'novel building blocks', '']
Pathway Therapeutics
	Developer of therapeutics against human diseases. The company offers PI3 kinase, an enzyme identified as active in cancer tumor development.
	['', 'drug development', ' ', 'cancer treatment', ' ', 'lifesciences and oncology', '']
Bridge Pharmaceuticals
	Provider of preclinical services. The company conducts drug development and preclinical services which include short and long-term in vivo studies ranging from acute to carcinogenicity protocols.
	['', 'preclinical service', ' ', 'drug development', ' ', 'reproductive toxicology', '']
OSS Healthcare
	Provider of seed funding to drug development companies. The company engages in searching for new oncology focused drugs and also provides seed funding for further drug development.
	['', 'drug development', ' oncology drugs']
ESBATech
	Developer of human antibody fragments for therapeutic applications. The company also provides drug development and development programs.
	['', 'therapeutic application', ' ', 'antibody fragment', ' ', 'drug development', '']
